Iqoniko is pleased to announce that it has been mandated by HEP-one GmbH as a capital market partner to support the company on its path to a planned stock market listing.
Central Role in Capital Market Preparation
As a capital market partner, Iqoniko will take on a central role in preparing HEP-one GmbH’s access to the capital markets. HEP-one plans to utilize this collaboration over the coming months to take further definitive steps toward capital market readiness. Iqoniko’s core responsibilities will include:
- Financing Concept: Developing a robust strategy for the upcoming clinical and regulatory steps.
- Investor Positioning: Strategically positioning the company with investors and industry partners.
- IPO Support: Providing comprehensive guidance throughout the journey to a successful stock exchange listing.
HEP-one Focus: Innovative Therapeutic Approaches
HEP-one develops therapeutic and diagnostic approaches for inflammatory and post-infectious diseases. The core of the platform is HEP-1, a human ezrin peptide that is currently being investigated for its inflammation-modulating, antiviral, and tissue-regenerative properties.
These development programs address highly relevant medical challenges, including:
- Long COVID / Post-COVID syndrome
- ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome)
- Ulcerative colitis
Voices on the Strategic Partnership
“The planned stock market listing is intended to support the financing of the next clinical and regulatory development steps, as well as the expansion of international research and industry partnerships.” — Dr. Ingolf Piechota, Project Manager, HEP-one GmbH
“We are particularly proud of this mandate and are delighted to be part of this innovation. If our work can contribute, even marginally, to making life a little easier for many Long COVID patients, then this is one of the most significant mandates for us.” — Miguel Moura, Managing Partner, Iqoniko Group
About HEP-one GmbH
HEP-one GmbH develops therapeutic and diagnostic approaches for inflammatory and post-infectious diseases, with the drug candidate HEP-1 serving as the central element of the platform.
